The Clorox Company (CLX) Stock Forecast
Data as of May 2, 2026Consumer Defensive · Current price $86.73 (-10.07%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 17, 2026 | Chris Carey | Wells Fargo | $125.00 | +44.1% |
| Feb 4, 2026 | Peter Grom | UBS | $121.00 | +39.5% |
| Jan 14, 2026 | Peter Grom | UBS | $115.00 | +32.6% |
| Nov 4, 2025 | Dara Mohsenian | Morgan Stanley | $125.00 | +44.1% |
| Nov 4, 2025 | Peter Grom | UBS | $119.00 | +37.2% |
| Nov 4, 2025 | Kaumil Gajrawala | Jefferies | $152.00 | +75.3% |
| Jul 15, 2025 | Lauren Lieberman | Barclays | $119.00 | +37.2% |
| May 7, 2025 | Lauren Lieberman | Barclays | $129.00 | +48.7% |
| May 6, 2025 | Javier Escalante | Evercore ISI | $140.00 | +61.4% |
| May 6, 2025 | Dara Mohsenian | Morgan Stanley | $150.00 | +73.0% |
| May 6, 2025 | Chris Carey | Wells Fargo | $142.00 | +63.7% |
| Mar 27, 2025 | Lauren Lieberman | Barclays | $139.00 | +60.3% |
| Oct 8, 2024 | Bonnie Herzog | Goldman Sachs | $132.00 | +52.2% |
| Oct 1, 2024 | Kaumil Gajrawala | Jefferies | $187.00 | +115.6% |
| Jul 19, 2024 | Lauren Lieberman | Barclays | $122.00 | +40.7% |
| May 2, 2024 | Chris Carey | Wells Fargo | $135.00 | +55.7% |
| Mar 26, 2024 | Kaumil Gajrawala | Jefferies | $145.00 | +67.2% |
| Jan 30, 2024 | Nik Modi | RBC Capital | $138.00 | +59.1% |
| Oct 5, 2023 | Olivia Tong | Raymond James | $185.00 | +113.3% |
| Sep 8, 2023 | Ken Goldman | J.P. Morgan | $153.00 | +76.4% |
Top Analysts Covering CLX
CLX vs Sector & Market
| Metric | CLX | Consumer Defensive Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 3.20 | 2.54 | 2.41 |
| Analyst Count | 25 | 12 | 18 |
| Target Upside | +21.6% | +1188.7% | +14.9% |
| P/E Ratio | 14.08 | -7.35 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $6.40B | $6.51B | $6.70B | 5 |
| 2026-09-30 | $1.65B | $1.72B | $1.79B | 2 |
| 2026-12-31 | $1.74B | $1.81B | $1.89B | 3 |
| 2027-03-31 | $1.71B | $1.78B | $1.86B | 3 |
| 2027-06-30 | $1.77B | $1.85B | $1.93B | 2 |
| 2027-09-30 | $1.73B | $1.81B | $1.88B | 2 |
| 2027-12-31 | $1.72B | $1.80B | $1.87B | 3 |
| 2028-03-31 | $1.72B | $1.79B | $1.87B | 2 |
| 2028-06-30 | $1.77B | $1.85B | $1.93B | 1 |
| 2029-06-30 | $7.35B | $7.64B | $7.81B | 4 |
| 2030-06-30 | $7.55B | $7.84B | $8.02B | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $5.64 | $5.88 | $6.14 | 5 |
| 2026-09-30 | $1.26 | $1.32 | $1.40 | 3 |
| 2026-12-31 | $1.43 | $1.51 | $1.59 | 4 |
| 2027-03-31 | $1.52 | $1.60 | $1.69 | 2 |
| 2027-06-30 | $2.05 | $2.16 | $2.28 | 2 |
| 2027-09-30 | $1.50 | $1.59 | $1.67 | 2 |
| 2027-12-31 | $1.45 | $1.53 | $1.61 | 2 |
| 2028-03-31 | $1.62 | $1.71 | $1.81 | 3 |
| 2028-06-30 | $2.05 | $2.17 | $2.29 | 3 |
| 2029-06-30 | $7.42 | $7.80 | $8.03 | 1 |
| 2030-06-30 | $7.77 | $8.16 | $8.40 | 1 |
Frequently Asked Questions
What is the analyst consensus for CLX?
The consensus among 25 analysts covering The Clorox Company (CLX) is Hold with an average price target of $118.78.
What is the highest price target for CLX?
The highest price target for CLX is $187.00, set by Kaumil Gajrawala at Jefferies on 2024-10-01.
What is the lowest price target for CLX?
The lowest price target for CLX is $115.00, set by Peter Grom at UBS on 2026-01-14.
How many analysts cover CLX?
25 analysts have issued ratings for The Clorox Company in the past 12 months.
Is CLX a buy or sell right now?
Based on 25 analyst ratings, CLX has a consensus rating of Hold (3.20/5) with a +21.6% upside to the consensus target of $118.78.
What are the earnings estimates for CLX?
Analysts estimate CLX will report EPS of $5.88 for the period ending 2026-06-30, with revenue estimated at $6.51B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.